Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
MVASImvasi.comMVASI is a bevacizumab biosimilar approved for treating multiple cancers including metastatic colorectal, non-squamous non-small cell lung, recurrent glioblastoma, metastatic renal cell, cervical, and ovarian cancers. It is the only bevacizumab biosimilar that provides Amgen support and resources for patients and practices.
Parse Score
